Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder

Journal of Clinical Psychiatry

Volumn 66, Issue 10, 2005, Pages 1326-1330

  Papakostas, George I ^a   Petersen, Timothy J ^a   Kinrys, Gustavo ^b   Burns, Alana M ^a   Worthington III, John J ^a   Alpert, Jonathan E ^a   Fava, Maurizio ^a   Nierenberg, Andrew A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CAMBRIDGE HEALTH ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL CONCENTRATION; NAUSEA; PRIORITY JOURNAL; REMISSION; RESTLESSNESS; SEDATION; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 27544477735     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1017     Document Type: Article

References (35)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
2. Petersen T, Papakostas GI, Nierenberg AA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. In press
3. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60:221-225
4. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180
5. Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. Psych Annals 1994;42:281-290
6. Papakostas GI, Petersen T, Denninger JW, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004;24:507-511
7. Ostroff RB, Nelson CJ. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256-259
8. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65:217-221
9. Rapaport M, Canuso C, Turkoz I, et al. Preliminary results from ARISe-RD (augmentation with risperidone in resistant depression) trial. Presented at the 43rd Annual New Clinical Drug Evaluation Unit Meeting; May 27-30, 2003; Boca Raton, Fla
10. Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003;64:1349-1356
11. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134
12. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002;16:779-788
13. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1- piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274:329-336
14. Inoue T, Domae M, Yamada K, et al. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996;277:137-143
15. Mitsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology (Berl) 1999;146:139-143
16. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20:612-627
17. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389
18. Li Z, Ichikawa J, Dai J, et al. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004;493:75-83
19. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002;441:137-140
20. Shapiro DA, Renock S, Arlington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411
21. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690
22. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136
23. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder J Clin Psychiatry 2002;63;763-771
24. Keck PE Jr, Marcus R, Tourkodimitris S, et al, Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658
25. Pigott TA, Carson WH, Saha AR, et al, for the Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056
26. Yokoi F, Grunder G, Biziere K, et al Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27:248-259
27. Worthington JJ III, Kinrys G, Wygant LE, et al. Aripiprazole as an augmenter of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11
28. Hellerstein DJ. Aripiprazole as an adjunctive treatment for refractory major depression [letter]. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1347-1348
29. First BM, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID I/P). New York, Biometrics Research, New York State Psychiatric Institute, 1995
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
31. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health. Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
32. Winans E. Aripiprazole. Am J Health Syst Pharm 2003;60:2437-2445
33. Otto MW. Statistical Methods for Clinical Psychopharmacology Trials. Research Designs and Methods in Psychiatry, Amsterdam, Netherlands: Elsevier; 1992
34. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, 3: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11
35. Nierenberg A, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003;64:192-196